[1]
|
World Health Organization (2021) Global Tuberculosis Report 2020. World Health Organization Document.
|
[2]
|
World Health Organization (2022) Global Tuberculosis Report 2021. World Health Organization Document.
|
[3]
|
Chan, E.D. and Iseman, M.D. (2008) Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Review. Current Opin-ion in Infectious Diseases, 21, 587-595. https://doi.org/10.1097/QCO.0b013e328319bce6
|
[4]
|
Xing, W., Zhang, R., Jiang, W., et al. (2021) Adherence to Multidrug Resistant Tuberculosis Treatment and Case Management in Chong-qing, China—A Mixed Method Research Study. Infection and Drug Resistance, 14, 999-1012.
https://doi.org/10.2147/IDR.S293583
|
[5]
|
Dillard, L.K., Martinez, R.X., Perez, L.L., et al. (2021) Prevalence of Aminoglycoside-Induced Hearing Loss in Drug-Resistant Tuberculosis Patients: A Systematic Review. Journal of Infec-tion, 83, 27-36.
https://doi.org/10.1016/j.jinf.2021.05.010
|
[6]
|
Bogale, L., Tsegaye, T., Abdulkadir, M., et al. (2021) Unfavorable Treatment Outcome and Its Predictors among Patients with Multidrug-Resistance Tuberculosis in Southern Ethiopia in 2014 to 2019: A Multi-Center Retrospective Follow-Up Study. Infection and Drug Resistance, 14, 1343-1355. https://doi.org/10.2147/IDR.S300814
|
[7]
|
Chaves-Torres, N.M., Fadul, S., Patiño, J., et al. (2021) Factors Asso-ciated with Unfavorable Treatment Outcomes in Patients with Rifampicin-Resistant Tuberculosis in Colombia 2013-2015: A Retrospective Cohort Study. PLOS ONE, 16, e0249565. https://doi.org/10.1371/journal.pone.0249565
|
[8]
|
林志浩, 丘小燕, 马晓慧, 等. 佛山市193例耐多药肺结核患者的治疗转归及影响因素分析[J]. 实用预防医学, 2022, 29(11): 1290-1294.
|
[9]
|
潘辰慧, 张顺先, 张少言, 等. 耐多药肺结核治疗转归的影响因素分析[J]. 解放军医学杂志, 2023, 48(9): 1040-1047.
|
[10]
|
李德富, 俞玉琪, 卢曲琴, 等. 江西省耐药结核病治疗现状与抗结核药治疗费用分析[J]. 现代预防医学, 2021, 48(18): 3425-3429.
|
[11]
|
Pan, Y., Yu, Y,, Lu, J., et al. (2022) Drug Resistance Pat-terns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study. Infec-tion and Drug Resistance, 15, 4137-4147.
https://doi.org/10.2147/IDR.S373125
|
[12]
|
Hirama, T., Sabur, N., Derkach, P., et al. (2020) Respiratory Syncytial Virus: Risk Factors for Drug-Resistant Tuberculosis at a Referral Centre in Toronto, Ontario, Canada: 2010-2016. Can-ada Communicable Disease Report, 46, 84-92.
https://doi.org/10.14745/ccdr.v46i04a05
|
[13]
|
de Dieu Longo, J., Woromogo, S.H., Tekpa, G., et al. (2023) Risk Factors for Multidrug-Resistant Tuberculosis in the Central African Republic: A Case-Control Study. Journal of Infection and Public Health, 16, 1341-1345.
https://doi.org/10.1016/j.jiph.2023.06.007
|
[14]
|
Tenzin, C., Chansatitporn, N., Dendup, T., et al. (2020) Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) in Bhutan: A Nationwide Case-Control Study. PLOS ONE, 15, e0236250.
https://doi.org/10.1371/journal.pone.0236250
|
[15]
|
符婷, 黄丽菊, 杨进军, 等. 海南省三亚市158例耐多药肺结核患者危险因素的Logistic回归分析[J]. 中国热带医学, 2020, 20(8): 789-793.
|
[16]
|
Tembo, B.P. and Malangu, N.G. (2019) Prevalence and Factors Associated with Multidrug/Rifampicin Resistant Tuberculosis among Suspected Drug Resistant Tuberculosis Patients in Botswana. BMC Infectious Diseases, 19, Article No. 779. https://doi.org/10.1186/s12879-019-4375-7
|
[17]
|
Loddenkemper, R., Sagebiel, D. and Brendel, A. (2002) Strategies against Multidrug-Resistant Tuberculosis. European Respiratory Journal, 20, 66s-77s. https://doi.org/10.1183/09031936.02.00401302
|
[18]
|
Antonio-Arques, V., Franch-Nadal, J., Moreno-Martinez, A., et al. (2022) Subjects with Diabetes Mellitus Are at Increased Risk for Developing Tuberculosis: A Cohort Study in an Inner-City District of Barcelona (Spain). Frontiers in Public Health, 10, Article ID: 789952. https://doi.org/10.3389/fpubh.2022.789952
|
[19]
|
Adegbite, B.R., Edoa, J.R., Abdul, J., et al. (2022) Non-Communicable Disease Co-Morbidity and Associated Factors in Tuberculosis Patients: A Cross-Sectional Study in Gabon. Eclinicalmedicine, 45, Article ID: 101316.
https://doi.org/10.1016/j.eclinm.2022.101316
|
[20]
|
Noubiap, J.J., Nansseu, J.R., Nyaga, U.F., et al. (2019) Global Prevalence of Diabetes in Active Tuberculosis: A Systematic Review and Meta-Analysis of Data from 2.3 Million Pa-tients with Tuberculosis. The Lancet Global Health, 7, e448-e460. https://doi.org/10.1016/S2214-109X(18)30487-X
|
[21]
|
Adane, H.T., Howe, R.C., Wassie, L., et al. (2023) Diabe-tes Mellitus Is Associated with an Increased Risk of Unsuccessful Treatment Outcomes among Drug-Susceptible Tuber-culosis Patients in Ethiopia: A Prospective Health Facility-Based Study. Journal of Clinical Tuberculosis and Other My-cobacterial Diseases, 31, Article ID: 100368.
https://doi.org/10.1016/j.jctube.2023.100368
|
[22]
|
Montes, K., Atluri, H., Tuch, H.S., et al. (2021) Risk Factors for Mortality and Multidrug Resistance in Pulmonary Tuberculosis in Guatemala: A Retrospective Analysis of Mandatory Reporting. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 25, Article ID: 100287. https://doi.org/10.1016/j.jctube.2021.100287
|
[23]
|
Habibi, M.R., Bakhtiar, A., Indiastuti, D.N., et al. (2022) Diabe-tes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019-2020. Jurnal Ilmiah Universitas Batanghari Jambi, 22, 537-543. https://doi.org/10.33087/jiubj.v22i1.1908
|
[24]
|
Iradukunda, A., Ndayishimiye, G.P., Sinarinzi, D., et al. (2021) Key Factors Influencing Multidrug-Resistant Tuberculosis in Patients under Anti-Tuberculosis Treatment in Two Centres in Burundi: A Mixed Effect Modelling Study. BMC Public Health, 21, Article No. 2142. https://doi.org/10.1186/s12889-021-12233-2
|
[25]
|
Agustin, H., Massi, M.N., Djaharuddin, I., et al. (2021) Analy-sis of CD4 and CD8 Expression in Multidrug-Resistant Tuberculosis Infection with Diabetes Mellitus: An Experimental Study in Mice. Annals of Medicine and Surgery, 68, Article ID: 102596. https://doi.org/10.1016/j.amsu.2021.102596
|
[26]
|
Kumar, A.K.H., Chandrasekaran, V., Kannan, T., et al. (2017) Anti-Tuberculosis Drug Concentrations in Tuberculosis Patients with and without Diabetes Mellitus. European Journal of Clinical Pharmacology, 73, 65-70.
https://doi.org/10.1007/s00228-016-2132-z
|